ZA201707335B - Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy - Google Patents

Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Info

Publication number
ZA201707335B
ZA201707335B ZA2017/07335A ZA201707335A ZA201707335B ZA 201707335 B ZA201707335 B ZA 201707335B ZA 2017/07335 A ZA2017/07335 A ZA 2017/07335A ZA 201707335 A ZA201707335 A ZA 201707335A ZA 201707335 B ZA201707335 B ZA 201707335B
Authority
ZA
South Africa
Prior art keywords
methods
cell therapy
barr virus
lymphoproliferative disorders
associated lymphoproliferative
Prior art date
Application number
ZA2017/07335A
Other languages
English (en)
Inventor
John O'REILLY Richard
Elizabeth Prockop Susan
Nasreen Hasan Aisha
DOUBROVINA Ekaterina
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56027234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201707335(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of ZA201707335B publication Critical patent/ZA201707335B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2017/07335A 2015-05-12 2017-10-27 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy ZA201707335B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160549P 2015-05-12 2015-05-12
PCT/US2016/031784 WO2016183153A1 (en) 2015-05-12 2016-05-11 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Publications (1)

Publication Number Publication Date
ZA201707335B true ZA201707335B (en) 2021-02-24

Family

ID=56027234

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/07335A ZA201707335B (en) 2015-05-12 2017-10-27 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Country Status (18)

Country Link
US (1) US10568908B2 (https=)
EP (1) EP3294304B1 (https=)
JP (2) JP7284556B2 (https=)
KR (1) KR102666781B1 (https=)
CN (1) CN107835690A (https=)
AR (1) AR104598A1 (https=)
AU (1) AU2016262484B2 (https=)
BR (1) BR112017024431B1 (https=)
CA (1) CA2984178C (https=)
CL (1) CL2017002846A1 (https=)
FR (1) FR23C1025I2 (https=)
IL (1) IL255581B (https=)
MX (1) MX386334B (https=)
NZ (1) NZ736675A (https=)
PH (1) PH12017501993A1 (https=)
RU (1) RU2720245C2 (https=)
WO (1) WO2016183153A1 (https=)
ZA (1) ZA201707335B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ749136A (en) 2016-05-25 2023-11-24 Council Queensland Inst Medical Res Methods of immunotherapy
AU2017326173B2 (en) * 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells
AU2018355145A1 (en) * 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
US20200350049A1 (en) * 2018-01-08 2020-11-05 Atara Biotherapeutics, Inc. Systems and methods for distributing cell therapies
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
JP2022554217A (ja) * 2019-10-23 2022-12-28 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 養子免疫療法
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
EP2365823B1 (en) 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
AU2011295845B2 (en) 2010-09-01 2016-09-22 Baylor College Of Medicine EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC)
EP3144008B1 (en) * 2012-05-08 2018-01-17 The John Hopkins University Compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes
CA2889064A1 (en) * 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
JP2016539929A (ja) * 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
MY189857A (en) * 2014-11-05 2022-03-14 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Also Published As

Publication number Publication date
MX2017014257A (es) 2018-04-20
US10568908B2 (en) 2020-02-25
CN107835690A (zh) 2018-03-23
CA2984178C (en) 2023-10-31
BR112017024431B1 (pt) 2021-10-13
KR102666781B1 (ko) 2024-05-20
MX386334B (es) 2025-03-18
US20180125891A1 (en) 2018-05-10
RU2017143151A (ru) 2019-06-13
HK1244697A1 (en) 2018-08-17
JP2018520095A (ja) 2018-07-26
EP3294304A1 (en) 2018-03-21
CL2017002846A1 (es) 2018-05-25
RU2720245C2 (ru) 2020-04-28
AR104598A1 (es) 2017-08-02
IL255581B (en) 2021-03-25
KR20180003575A (ko) 2018-01-09
JP2021119154A (ja) 2021-08-12
RU2017143151A3 (https=) 2019-10-29
AU2016262484A1 (en) 2018-01-04
NZ736675A (en) 2023-03-31
IL255581A (en) 2018-01-31
CA2984178A1 (en) 2016-11-17
AU2016262484B2 (en) 2021-10-21
PH12017501993A1 (en) 2018-03-26
WO2016183153A1 (en) 2016-11-17
JP7284556B2 (ja) 2023-05-31
FR23C1025I1 (fr) 2023-07-21
EP3294304B1 (en) 2020-01-29
FR23C1025I2 (fr) 2025-04-18
BR112017024431A2 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL278150A (en) A transgenic bacterium for the treatment of diseases related to hyperammonemia
GB2573664B (en) Viral methods of T cell therapy
IL282655A (en) Methods of treating developmental disorders using pipradrol
ZA201707335B (en) Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
IL253244A0 (en) Methods for treating retinal diseases
IL253285B (en) A method for treating a spinal disc
GB201701673D0 (en) Methods of well treatment
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
SG11201705401YA (en) Methods to improve cell therapy
GB201521357D0 (en) Methods for predicting response to anti-TNF therapy
EP3209614A4 (en) Water treatment reactor
GB201410116D0 (en) Method of treatment
GB201407101D0 (en) New process for the treatment of high sulphate waters
ZA201705877B (en) Method of treating diseases
GB2540492B (en) Control of power distribution system
EP3145543A4 (en) Treatment of eosinophil or mast cell related disorders
IL245538A0 (en) Treatment methods for abnormal muscle activity
IL253847A0 (en) Methods of treating diseases
GB201416832D0 (en) Methods of treatment
IL267231A (en) Methods of treating diseases associated with ilc2 cells
PT3172297T (pt) Método para tratar algas
HUE051834T2 (hu) A növényi vírusok biológiai ellenõrzése
IL262951A (en) Methods of drug therapy associated with ilc3 cells
GB201512139D0 (en) Methods of treatment